Dr. Angela Shen serves as Vice President of Strategic Innovation Leaders at MGB Innovation and Head of Regulatory at the MGB Gene and Cell Therapy Institute. In these roles, she brings extensive expertise in translational medicine, clinical development, and regulatory affairs, guiding the advancement of novel therapies in development at Mass General Brigham.

Dr. Shen is a seasoned biotech executive with over 20 years of experience developing innovative therapies for oncology and rare diseases, spanning all stages of drug development. Before joining Mass General Brigham, she served as Chief Medical Officer (CMO) for several venture-backed biotech startups, where she honed her expertise in cell and gene therapies. During her tenure at Novartis, Dr. Shen was extensively involved with in-licensing University of Pennsylvania’s CAR-T technology, and led the clinical team that designed and launched industry’s first multi-site registration CAR-T trial, resulting in the landmark FDA approval of Kymriah. Her contributions to the development of new therapies also extend to her work at Exelixis and Johnson & Johnson.

Dr. Shen holds a BS through Rensselaer’s accelerated biomedical program, an MD from Albany Medical College, and MBA from NYU Stern School of Business. Her deep expertise and leadership have been instrumental in advancing novel treatments for patients with unmet medical needs.